NICE, the National Institute for Health and Care Excellence, plays a significant role in the cost per Quality-Adjusted Life Year (QALY) threshold debate.

About 50% will ultimately relapse post-transplant. The latest decision by NICE ensures that those patients in the third line setting will continue to have access to CAR-T cell therapy.